CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ViRelieve is developing new therapeutics to combat respiratory viruses like respiratory syncytial virus and parainfluenza. Their research focuses on blocking key processes in virus infection, aiming to fill a significant gap in effective treatments for these widespread illnesses.
Human respiratory viruses cause economic and health burdens worldwide because there are no effective therapies.
We have discovered a novel approach to stop their infection.
The human respiratory viruses parainfluenza (PIV) and respiratory syncytial (RSV) viruses cause economic and health burdens worldwide.
While RSV is the number one cause of death in children under 5 years old, with over 33M new cases occurring annually worldwide, PIV is the cause of 4-5% of all respiratory infections and 6-11%…
VIRELIEVE THERAPEUTICS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
